Abstract:T he study by Guo et al examines the in vitro protective effect of culture supernatants from 2 probiotic bacteria, Bifidobacterium infantis and Lactobacillus acidophilus, on intestinal epithelial barrier function. Using an epithelial colorectal adenocarcinoma cell line (Caco-2) assay, the authors demonstrate that preincubation with sterile, cell-free culture supernatants (CFS) from either of these 2 bacterial strains prevented interleukin-1b-induced intestinal barrier permeability as measured by transepithelial electrical resistance and fluorescein isothiocyanate-labeled dextran flux. Protection was mediated by preventing both interleukin-1b-induced increases in tight junction protein claudin-1 expression and nuclear factor-kB activation. These observations add to a growing body of evidence that probiotic bacteria and, more specifically, their cell-associated and secreted products promote integrity of epithelial barrier function and maintenance of intestinal homeostasis (1–4). pH is a key determinant of bioactivity; L acidophilus and B infantis used in this study produce lactate that acidifies the conditioned culture medium and likely influences the bioactivity of associated microbial-derived products. In the described study, the authors adjust the cell-free supernatant to pH 7.4. Luminal pH in the healthy lower gastrointestinal tract is, however, site-specific and ranges from 5.5 to 7.5 (though patients with gastrointestinal disease frequently exhibit deviations from these mean values (5)). This raises the possibility that the bioactivity of the CFS in vitro may be distinct from in vivo conditions in the gastrointestinal tract and supports screening the bioactivity of these conditioned culture media across the range of pH conditions found in the lower gut. Questions also naturally arise as to whether this beneficial effect of probiotic strain-derived CFS is exclusive to these probiotic species, or if CFS from other bacteria, including those typically considered pathogenic, may also derive a similar effect under the epithelial culture conditions examined. Although it is critical to understand the efficacy of single species and the mechanisms by which they promote barrier function, the complex microbial communities found in the gastrointestinal tract (human microbiome), even in the earliest phases of life, may influence bioavailability of consumed or orally administered bioactives. Microbial members within the human gastrointestinal microbiome compete with each other and the host for resources. To date, the microbial-derived products that promote barrier function include short-chain fatty acids such as acetate produced by Bifidobacteria, which prevent epithelial barrier disruption through tumor necrosis factor-a induction (1). Such products, however, represent attractive carbon sources for a broad range of gastrointestinal organisms (6–8). Hence, whether oral supplementation with probiotic-derived products would lead to effective epithelial bioavailbility in the distal gastrointestinal tract in humans remains to be determined. Ideally, a single microbial-derived product within the conditioned media of these species promotes epithelial integrity. There are, however, multiple candidate mechanisms and likely as many microbial-derived and associated products that may promote barrier function. These may include pH modification via production of lactic acid or other short-chain fatty acids (7), lipid-derived induction of anti-inflammatory innate and adaptive immune responses (9), and/or triggering of toll-like receptor signaling pathways (4,10), which may act synergistically to promote epithelial integrity. Moreover, the gastrointestinal tract is overtly colonized from early life, so while promoting barrier function may reduce proinflammatory responses it is unlikely to correct associated gut microbial dysbioses. As such, the efficacy of such a therapeutic strategy may be enhanced by preconditioning the gastrointestinal tract with microbial-derived products to promote barrier integrity and reduce proinflammatory responses, followed by oral supplementation with a relatively simple and defined inoculum of microbial species to promote appropriate microbiome (re)development. Probiotics have gained enormous interest in recent years as a means to promote intestinal homeostasis; however, much more work is needed to fully elucidate their mechanism(s) of action. The observations reported in this study are important because they provide initial evidence for promotion of barrier function via probiotic-derived products. Understanding the mechanism(s) by which microbes and their products beneficially alter host physiology holds much promise for a broad range of conditions, not least as a precursor treatment for highly vulnerable populations such as premature neonates at high risk of necrotizing enterocoilitis.

Probiotic Mixture Golden Bifido Prevents Neonatal Escherichia Coli K1 Translocation Via Enhancing Intestinal Defense

Protective Effects of Bifidobacteria on Intestines in Newborn Rats with Necrotizing Enterocolitis and Its Regulation on TLR2 and TLR4.

Probiotic Pre-Administration Reduces Mortality in a Mouse Model of Cecal Ligation and Puncture-Induced Sepsis.

Lactobacillus Rhamnosus Gg Treatment Improves Intestinal Permeability And Modulates Microbiota Dysbiosis In An Experimental Model Of Sepsis

Lactobacillus Rhamnosus GG Supernatant Enhance Neonatal Resistance to Systemic Escherichia Coli K1 Infection by Accelerating Development of Intestinal Defense

Lactobacillus Rhamnosusgg Suppresses MeningiticE. Colik1 Penetration Across Human Intestinal Epithelial Cells in Vitro and Protects Neonatal Rats Against Experimental Hematogenous Meningitis

A Novel Postbiotic From Lactobacillus rhamnosus GG With a Beneficial Effect on Intestinal Barrier Function

Inhibition of the Adherence and Invasion of E. Coli K1 by Probiotics

Effects of Multispecies Probiotic on Intestinal Microbiota and Mucosal Barrier Function of Neonatal Calves Infected With E. coli K99

Lactation-dependent Vertical Transmission of Natural Probiotics from the Mother to the Infant Gut Through Breast Milk.

Lactobacillus Rhamnosus GG Conditioned Medium Prevents E. Coli Meningitis by Inhibiting Nuclear Factor-Κb Pathway

Protective Effects and Mechanism of a Novel Probiotic Strain Ligilactobacillus salivarius YL20 against Cronobacter sakazakii-Induced Necrotizing Enterocolitis In Vitro and In Vivo

Oral Administration of a Select Mixture of Bacillus Probiotics Affects the Gut Microbiota and Goblet Cell Function Following Escherichia Coli Challenge in Newly Weaned Pigs of Genotype MUC4 That Are Supposed to Be Enterotoxigenic E. Coli F4ab/ac Receptor Negative.

Secreted Metabolites of Bifidobacterium Infantis and Lactobacillus Acidophilus Protect Immature Human Enterocytes from IL-1β-Induced Inflammation: A Transcription Profiling Analysis

Mechanisms for Lactobacillus rhamnosus treatment of intestinal infection by drug-resistant Escherichia coli

Bifidobacterium longum K5 Prevents Enterohaemorrhagic Escherichia coli O157:H7 Infection in Mice through the Modulation of the Gut Microbiota

Changes in Gut Microbiota by the <i>Lactobacillus casei</i> Anchoring the K88 Fimbrial Protein Prevented Newborn Piglets From Clinical Diarrhea

Bifidobacterium bifidum E3 Combined with Bifidobacterium longum subsp. infantis E4 Improves LPS-Induced Intestinal Injury by Inhibiting the TLR4/NF-κB and MAPK Signaling Pathways In Vivo

Promotion of Epithelial Barrier Integrity Via Probiotic-derived Products.

<i>Bifidobacterium bifidum</i> E3 Combined with <i>Bifidobacterium</i> <i>longum subsp. infantis</i> E4 Improves LPS-Induced Intestinal Injury by Inhibiting the TLR4/NF-B and MAPK Signaling Pathways <i>In Vivo</i>

Changes in Gut Microbiota by the Lactobacillus casei Anchoring the K88 Fimbrial Protein Prevented Newborn Piglets From Clinical Diarrhea